Results 51 to 60 of about 4,386 (137)

Glucocorticoids and HPA axis regulation in the stress–obesity connection: A comprehensive overview of biological, physiological and behavioural dimensions

Clinical Obesity, Volume 15, Issue 2, April 2025.
Summary Chronic stress, characterized by increased long‐term exposure to the glucocorticoid hormone cortisol, is increasingly linked to obesity development. Still, various knowledge gaps persist, including on underlying pathophysiological mechanisms. The aim of the current review is to provide the latest insights on the connection between stress and ...
Robin Lengton, Myrte Schoenmakers, Brenda W. J. H. Penninx, Mariëtte R. Boon, Elisabeth F. C. van Rossum   +4 more
wiley   +1 more source

Mifepristone: A potential postcoital contraceptive

, 2001
Mifepristone is an orally-active progesterone receptor antagonist. When a single dose of mifepristone is given in the mid- or late follicular phase, it may diminish or inhibit the luteinising hormone (LH) surge.
Ho, PC
core   +1 more source

Rethinking Reproductive Governance: What Can Public Administration on the Island of Ireland Learn From Abortion Accompaniment?

Public Administration, EarlyView.
ABSTRACT The recent decriminalization of abortion marked a crucial step toward improved reproductive care on the island of Ireland. However, this has not translated into fully accessible abortion provision—barriers, including inaccessible services, persist, leaving gaps that public administration has not formally addressed. In response, informal actors,
Anna Theresa Schmid
wiley   +1 more source

Mifepristone followed by misoprostol compared with placebo followed by misoprostol as medical treatment for early pregnancy loss (the Triple M trial): A double-blind placebo-controlled randomised trial

EClinicalMedicine, 2021
Background: Worldwide, millions of women seek treatment for early pregnancy loss (EPL) annually. Medical management with misoprostol is widely used, but only effective 60% of the time.
Charlotte Hamel, Sjors Coppus, Joyce van den Berg, Esther Hink, Jacoba van Seeters, Paul van Kesteren, Ashley Merién, Bas Torrenga, Rafli van de Laar, Josien Terwisscha van Scheltinga, Ingrid Gaugler-Senden, Peppino Graziosi, Minouche van Rumste, Ewka Nelissen, Frank Vandenbussche, Marcus Snijders   +15 more
doaj   +1 more source

Mifepristone for uterine fibroids

, 2012
BackgroundUterine fibroids are the most common benign uterine tumours present in women of reproductive age. Mifepristone (RU-486) competitively binds and inhibits progesterone receptors.
Tristan, Mario, Ramírez-Morera, Anggie, Steed, Antonia, Stone, Peter, Orozco, Leonardo J   +4 more
core   +1 more source

Trends in Non‐Resident Abortion Rates in Illinois From 2001–2018

Perspectives on Sexual and Reproductive Health, EarlyView.
ABSTRACT Objective To describe trends in resident and non‐resident abortion rates in Illinois between 2001 and 2018. Methods Using Illinois Department of Public Health data, we calculated the resident abortion rate (abortions obtained by Illinois residents per 1000 reproductive age Illinois residents) and the non‐resident abortion rate (abortions ...
Erica S. Bishop, Elizabeth Gray, Leanne R. McCloskey   +2 more
wiley   +1 more source

Mifepristone: Contraceptive and non-contraceptive uses

, 2002
Mifepristone is an orally active progesterone antagonist. It can be used for both contraceptive and non-contraceptive clinical indications. It is a very effective drug for emergency contraception with a low incidence of side effects. There is a potential
Pak, CH, Oi, ST, Ng, EHY
core   +1 more source

Safety of Intra‐Amniotic and Intra‐Fetal Digoxin Administration in Late Second‐Trimester Abortion by Dilation and Evacuation

Perspectives on Sexual and Reproductive Health, EarlyView.
ABSTRACT Objective The study's purpose was to determine the safety of two routes and doses of digoxin through assessment of systemic absorption, cardiac rhythm, and coagulation parameters injected as part of second‐trimester dilation and evacuation abortion.
Eleanor A. Drey, Nora Goldschlager, Neal L. Benowitz, Abby Sokoloff, Rebecca A. Jackson   +4 more
wiley   +1 more source

Development of specific glucocorticoid receptor antagonists

European Journal of Psychotraumatology, 2012
Background / Methods : Mifepristone, a potent glucocorticoid receptor (GR) and progesterone receptor (PR) antagonist, has recently become the first medication approved for the treatment of Cushing's syndrome, the archetypal illness of cortisol ...
Joseph K. Belanoff
doaj   +1 more source

Mifepristone occupies the coactivator protein space.

, 2013
A. ancSR2–progesterone–mifepristone (protein, slate blue; mifepristone, magenta) was overlaid with ancestral corticoid receptor–deoxycorticosterone–hSHP NRBox1 (PDB accession code: 2Q3Y) complex.
Jennifer K. Colucci (119487), Eric A. Ortlund (119490)   +1 more
core   +1 more source